Stock Upgrades Today Highlight Top Picks

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  19 Dec 2025
 

•   ACM  
   
  0.00%
•   ACN  
   
  0.00%
•   AFG  
   
  0.00%
•   AGNC  
   
  0.00%
•   ALMS  
   
  0.00%

$ACM received a Buy rating from Truist Securities, though the price target was lowered from $148 to $126. Despite a recent 14% pullback, AECOM shows potential for value-minded investors looking for oversold industrials with momentum indicators signaling opportunity.

$ACN saw Morgan Stanley upgrade its rating to Overweight and raise the target to $320, reflecting confidence in Accenture AI-driven growth and strong market positioning. The resilience makes it a compelling pick for tech-focused portfolios.

$AFG maintained an Outperform rating from Keefe Bruyette & Woods with a price forecast suggesting 22.59% upside. First American Financial continues to draw attention for its solid fundamentals and attractive risk/reward profile.

$AGNC maintained Outperform ratings for both its common and preferred stock, signaling steady confidence despite small projected downside. Investors looking for income-oriented plays may find AGNC appealing.

$ALMS kept its Buy rating with an impressive 75.07% upside forecast, highlighting strong potential in the specialty materials sector. Alumis offers traders a high-reward setup if momentum continues.

$AMAT maintained a Buy rating with only modest upside, suggesting steady, low-risk exposure to semiconductor and materials supply chains rather than explosive moves.

$AVAV initiated coverage with a Buy rating, showing optimism in AeroVironment future in clean energy technologies. Its recent rally underscores investor appetite for innovation-driven plays.

$AXTA retained its Buy rating with a 15.52% upside forecast, offering exposure to industrial coatings and resilient end markets.

$BIRK maintained an Outperform with a notable 75% projected upside, reflecting optimism in the consumer discretionary segment and strong brand momentum.

$CCL held a Buy rating with a 24.65% upside, as Carnival travel recovery story remains compelling amid higher-than-average trading volume.

$CE retained Buy coverage with a 25.90% upside, reflecting confidence in chemical manufacturing and robust industrial demand.

$CMI maintained a Buy rating with modest upside, highlighting Cummins’ strong fundamentals and steady performance in engine technologies.

$COUR continued with Outperform coverage and a 55.59% upside, signaling strong growth prospects in online education and tech-enabled learning platforms.

$CRMD kept its Buy rating, offering 62.65% upside potential, signaling strong interest in biotech developments and therapeutics.

$EMN maintained a Buy rating with 15.63% upside, reflecting consistent chemical sector performance and industrial demand.

$EW was upgraded to Overweight by JP Morgan, offering 13% upside as Edwards Lifesciences gains traction in medical devices.

$EXOD retained a Buy rating with a massive 171.36% upside, making Exodus Movement a high-reward biotech play for aggressive traders.

$GEV upgraded to Buy, offering 7.48% upside as GE Vernova gains traction in renewable energy solutions.

$GIS maintained Market Perform with a 13.82% upside, providing steady exposure in consumer staples.

$GM maintained an Outperform rating, though with slight downside projected, offering cautious exposure in automotive markets.

$HCA maintained Outperform coverage, reflecting modest upside yet stable healthcare fundamentals.

$HOOD initiated coverage with a Buy rating, capitalizing on rapid growth and scalable fintech opportunities.

$HOUS remained Market Perform with downside, suggesting limited near-term momentum in real estate.

$HUT maintained Buy coverage despite projected downside, highlighting volatility in cryptocurrency mining exposure.

$INSM retained Buy and Outperform coverage with 30.50% upside, signaling strong potential in biotech therapies.

$IRTC maintained Buy rating with 33.11% upside, reflecting growth in wearable medical technologies.

$ITGR maintained Buy coverage, offering modest 9.81% upside in medical device manufacturing.

$LEN maintained Buy coverage with 19.61% upside, showing strong positioning in residential construction.

$LNTH maintained Buy rating with 27.30% upside, signaling opportunity in diagnostic imaging and nuclear medicine.

$LRCX maintained Buy rating with modest upside but strong volume, reflecting semiconductor strength and market confidence.

$MRK upgraded to Outperform, offering 5.40% upside in pharmaceutical exposure with solid pipeline prospects.

$MTG remained Market Perform with slight downside, signaling limited near-term gains in mortgage insurance.

$MTZ maintained Buy rating with 18.60% upside, reflecting strong industrial services growth.

$MU retained Buy and Outperform ratings with a slight projected downside yet remains key for semiconductor exposure.

$NBR upgraded to Overweight with 1.99% upside, suggesting modest near-term opportunity in oilfield services.

$NVDA maintained Strong Buy with 47.04% upside, reflecting excitement around AI adoption and high-growth tech momentum.

$PACS maintained Buy rating with 11.37% downside, offering risk-aware exposure to specialty tech services.

$PEN maintained Buy and was upgraded to Overweight, though upside remains limited, reflecting medical device resilience.

$PGY remained Buy-rated, highlighting AI-driven fintech potential with moderate short-term gains.

$PH maintained Buy coverage, offering 6.67% upside through industrial automation and precision engineering.

$PPG maintained Buy rating with 17.82% upside, reflecting strength in coatings and industrial supply chains.

$RDN maintained Market Perform with 7.57% upside, providing steady exposure in mortgage-related financials.

$RIVN maintained Buy coverage, continuing a strong rally in EV markets after positive analyst notes.

$RKT remained Market Perform with 10.85% upside, signaling steady returns in mortgage tech.

$RNGR upgraded to Overweight with 24.73% upside, highlighting energy services strength and recovery potential.

$SABS maintained Buy rating with 129.26% upside, signaling a high-reward biotech opportunity.

$SERV initiated Outperform coverage, projecting 86.37% upside in robotics and logistics solutions.

$SHAK upgraded to Neutral, projecting 35.01% upside as casual dining and consumer engagement improve.

$SHW upgraded to Buy, reflecting 21.09% upside in industrial coatings leadership.

$SIBN maintained Buy rating with 27.01% upside, providing targeted medical device growth exposure.

$URI maintained Buy with 26.76% upside, reflecting strength in equipment rental and industrial services.

$VITL maintained Buy coverage with 70.22% upside, highlighting momentum in sustainable agriculture and consumer products.

$VPG initiated Buy coverage with 9.73% upside, reflecting precision instruments growth.

$VRCA upgraded to Buy with 106.19% upside, signaling strong potential in biotech therapeutics and dermatology.

View All Headlines